SCHEMBL14616781

SCHEMBL14616781

COCCn1c(-c2cnc(-c3ccc(Cl)cc3)[nH]2)nc2ccc(C)cc21

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RIPK2 O43353 1/20 0.64
▸ CASR P41180 1/20 0.41
▸ HPGD P15428 2/20 0.41
▸ HSD17B10 Q99714 4/20 0.41
▸ KDM4E B2RXH2 3/20 0.41
▸ RECQL P46063 1/20 0.41
▸ ALDH1A1 P00352 6/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ CYP1A2 P05177 4/20 0.40
▸ CYP3A4 P08684 3/20 0.40
▸ CYP2C9 P11712 3/20 0.40
▸ CASP1 P29466 3/20 0.40
▸ CASP7 P55210 3/20 0.40
▸ TSHR P16473 2/20 0.40
▸ ALOX15 P16050 2/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ SCN2A Q99250 1/20 0.39
▸ CYP2D6 P10635 2/20 0.39
▸ MEN1 O00255 2/20 0.39
▸ KMT2A Q03164 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14616779 0.92 RIPK2 (0.72) RIPK2CASRHPGDHSD17B10KDM4E
SCHEMBL14616778 0.90 RIPK2 (0.62) RIPK2CASRHPGDHSD17B10KDM4E
SCHEMBL12284542 0.88 RIPK2 (0.66) RIPK2CASRHPGDHSD17B10KDM4E
SCHEMBL14616784 0.87 RIPK2 (0.71) RIPK2PTGER4
SCHEMBL14616783 0.85 RIPK2 (0.73) RIPK2KDM4EALDH1A1MAPTTP53
SCHEMBL12284277 0.84 RIPK2 (0.64) RIPK2CASRHPGDHSD17B10KDM4E
SCHEMBL14616831 0.83 RIPK2 (0.47) RIPK2CASRHPGDHSD17B10KDM4E
SCHEMBL14616777 0.82 RIPK2 (0.67) RIPK2CASRHPGDHSD17B10KDM4E
SCHEMBL14616800 0.82 RIPK2 (0.53) RIPK2CASRHPGDHSD17B10KDM4E
SCHEMBL14575975 0.81 RIPK2 (0.43) RIPK2CASRHPGDHSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130018039-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-17 — — US disclosed
US-20130018039-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130018039-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS MAP3K19, MAP3K20, MAP3K3 RIPK2 255/4885CASR 2479/4885HPGD 3449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback